In addition to clinical and patient-reported outcomes (PRO) analyses, evaluating the economic burden of liver diseases and the cost-effectiveness of treatment and management strategies is essential to fully understand their overall impact of liver disease. Members of COR-LD have been leaders in this field for over two decades.
The COR-LD team conducted some of the earliest economic analyses of hepatitis C virus (HCV) and its treatment and was among the first to quantify the economic impact of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Additional work has addressed cholestatic liver diseases, complications of cirrhosis, liver transplantation, and other chronic liver conditions.
COR-LD investigators utilize advanced health economic methods, including Markov and decision-analytic models, as well as large administrative databases (e.g., Medicare, National Inpatient Sample, and Medical Expenditure Panel Survey) to assess healthcare utilization, costs, and cost-effectiveness. Importantly, the team has pioneered integrated analyses combining clinical, PRO, and economic outcomes to evaluate the overall value of liver disease treatment strategies.